

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

**VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON THE ONGOING CLINICAL STUDIES FOR
BATOCLIMAB (HBM9161)**

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about its latest business updates.

The board of directors of the Company (the “**Board**”) is pleased to announce that the data for first interim analysis of the phase II clinical study of batoclimab (HBM9161) for the treatment of patients with myasthenia gravis (MG) has been submitted to the China Center for Drug Evaluation (the “**CDE**”). The Company has obtained full endorsement from the CDE on its plan to proceed with the phase III pivotal trial for batoclimab.

For the phase II clinical study of batoclimab for the treatment of patients with immune thrombocytopenia (ITP), an independent data monitoring committee has reviewed the study data and confirmed that no safety concerns were identified, including the lipid test results.

The phase Ib/IIa study of batoclimab for treatment of patients with neuromyelitis optica spectrum disorder (NMOSD) is ongoing as planned and no additional safety signal has been identified.

Batoclimab (HBM9161), a fully human anti-FcRn mAb, blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies and leads to the treatment of pathogenic IgG-mediated autoimmune diseases. Earlier studies demonstrated that batoclimab is well tolerated and can rapidly reduce total IgG. These findings make batoclimab the first anti-FcRn to demonstrate a sustained IgG reduction in both Chinese and Caucasian populations when administered via subcutaneous (SC) injection.

Cautionary Statement: We cannot guarantee that we will be able to develop, or ultimately market, batoclimab (HBM9161) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, June 2, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Mai-Jing Liao as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.